BAY3498264
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors Harboring KRAS G12C Mutation
Conditions
Advanced Solid Tumors Harboring KRAS G12C Mutation
Trial Timeline
Nov 8, 2024 → Mar 7, 2028
NCT ID
NCT06659341About BAY3498264
BAY3498264 is a phase 1 stage product being developed by Bayer for Advanced Solid Tumors Harboring KRAS G12C Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06659341. Target conditions include Advanced Solid Tumors Harboring KRAS G12C Mutation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06659341 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumors Harboring KRAS G12C Mutation